{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T06:30:33Z","timestamp":1764916233067,"version":"3.46.0"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Currently, the primary treatments for cervical cancer patients are surgery or chemoradiotherapy, with a lack of standardized pharmacological therapies. Here, we report the construction of a Fab fragment phage display antibody library with a capacity of 10^9, derived from peripheral blood mononuclear cells of 15 women vaccinated against HPV. Through four rounds of screening, one clone, VLP18-Fab, specifically binding to HPV18 virus-like particles (HPV18 VLP), was selected from 40 clones. Additionally, the VLP18-Fab antibody demonstrated a highly significant and dose-dependent neutralizing activity against HPV18 pseudoviruses (P &amp;lt; 0.0001).Moreover,following identification, the structure of the antibody-antigen binding complex was simulated using BIOVIA Discovery Studio, which included the identification of potential binding sites. Overall, this study underscores the potential of phage-displayed antibody library technology for screening neutralizing antibodies and provides valuable insights for the design of HPV vaccines based on structural studies of antigen-antibody complexes.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1712231","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T06:25:11Z","timestamp":1764915911000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Screening and identification of human HPV18VLP neutralizing antibodies from women receiving HPV vaccine"],"prefix":"10.3389","volume":"16","author":[{"given":"Yaru","family":"Gu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenhao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinrui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bixia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Houyi","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yexiang","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renjian","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qianfei","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(19)30482-6","article-title":"Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis","volume":"8","author":"Arbyn","year":"2019","journal-title":"Lancet Global Health"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25516","article-title":"Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008","volume":"127","author":"Ferlay","year":"2010","journal-title":"Int J Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA: Cancer J Clin"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02478","article-title":"Advances in designing and developing vaccines, drugs and therapeutic approaches to counter human papilloma virus","volume":"9","author":"Dadar","year":"2018","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12879-014-0677-y","article-title":"High genital prevalence of cutaneous human papillomavirus DNA on male genital skin: the HPV Infection in Men Study","volume":"14","author":"Sichero","year":"2014","journal-title":"BMC Infect Diseases"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.3802\/jgo.2016.27.e51","article-title":"Immunotherapy for human papillomavirus-associated disease and cervical cancer: review of clinical and translational research","volume":"27","author":"Lee","year":"2016","journal-title":"J Gynecologic Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.678318","article-title":"Potent neutralizing humanized antibody with topical therapeutic potential against HPV18-related cervical cancer","volume":"12","author":"Huang","year":"2021","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.83458-0","article-title":"Association of serum and mucosal neutralizing antibodies to human papillomavirus type 16 (HPV-16) with HPV-16 infection and cervical disease","volume":"89","author":"Mbulawa","year":"2008","journal-title":"J Gen Virol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.77.17.9369-9377.2003","article-title":"Passive immunization with neutralizing antibodies interrupts the mouse mammary tumor virus life cycle","volume":"77","author":"Mpandi","year":"2003","journal-title":"J Virol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.148","article-title":"Passive immunotherapy of viral infections: \u2018super-antibodies\u2019 enter the fray","volume":"18","author":"Walker","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"94","DOI":"10.3390\/v10020094","article-title":"Expert views on HPV infection","volume":"10","author":"McBride","year":"2018","journal-title":"Viruses"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2013.11.002","article-title":"The human papillomavirus family and its role in carcinogenesis","volume":"26","author":"Tommasino","year":"2014","journal-title":"Semin Cancer Biol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-020-0673-7","article-title":"Analysis of Ugandan cervical carcinomas identifies human papillomavirus clade\u2013specific epigenome and transcriptome landscapes","volume":"52","author":"Gagliardi","year":"2020","journal-title":"Nat Genet"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2841","DOI":"10.1038\/s41467-020-16639-1","article-title":"Rational design of a multi-valent human papillomavirus vaccine by capsomere-hybrid co-assembly of virus-like particles","volume":"11","author":"Wang","year":"2020","journal-title":"Nat Commun"},{"key":"B15","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/1743-422X-3-83","article-title":"Characterization of neutralizing epitopes within the major capsid protein of human papillomavirus type 33","volume":"3","author":"Roth","year":"2006","journal-title":"Virol J"},{"key":"B16","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1007\/s12033-019-00156-8","article-title":"Phage display libraries: from binders to targeted drug delivery and human therapeutics","volume":"61","author":"Sioud","year":"2019","journal-title":"Mol Biotechnol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1590\/S1415-47572005000100001","article-title":"phage display technology -applications and innovations","volume":"28","author":"Arap","year":"2017","journal-title":"Genet Mol Biol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/c2015-0-05654-4","article-title":"Harnessing the power of viruses","author":"Marintcheva","year":"2017"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01986","article-title":"Phage display derived monoclonal antibodies: from bench to bedside","volume":"11","author":"Alfaleh","year":"2020","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2010.04.006","article-title":"Analysis of the epitope and neutralizing capacity of human monoclonal antibodies induced by hepatitis B vaccine","volume":"87","author":"Tajiri","year":"2010","journal-title":"Antiviral Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2016.67","article-title":"Combinatorial antibody libraries: new advances, new immunological insights","volume":"16","author":"Lerner","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"B22","article-title":"Phage display: a laboratory manual","volume":"4","author":"Barbas Iii","year":"2001","journal-title":"Q Rev Biol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1101\/pdb.prot065573","article-title":"Generation of human scFv antibody libraries: PCR amplification and assembly of light- and heavy-chain coding sequences","volume":"2011","author":"Andris-Widhopf","year":"2011","journal-title":"Cold Spring Harb Protoc"},{"key":"B24","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3389\/fchem.2014.00015","article-title":"Unnatural amino acid incorporation in E. coli: current and future applications in the design of therapeutic proteins","volume":"2","author":"Wals","year":"2014","journal-title":"Front Chem"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1021\/jo050278f","article-title":"Protein glycosylation: new challenges and opportunities","volume":"70","author":"Wong","year":"2005","journal-title":"J organic Chem"},{"key":"B26","doi-asserted-by":"publisher","first-page":"0","DOI":"10.1016\/0022-2836(91)90498-U","article-title":"By-passing immunization: Human antibodies from V-gene libraries displayed on phage","volume":"222","author":"Marks","year":"1991","journal-title":"J Mol Biol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2019.06.009","article-title":"Trends in therapeutic antibody affinity maturation: From in-vitro towards next-generation sequencing approaches","volume":"212","author":"Tabasinezhad","year":"2019","journal-title":"Immunol Lett"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1712231\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T06:25:11Z","timestamp":1764915911000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1712231\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":27,"alternative-id":["10.3389\/fimmu.2025.1712231"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1712231","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,5]]},"article-number":"1712231"}}